Enanta Pharmaceuticals Inc
ENTA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001177648
No open-market purchases or sales by Enanta Pharmaceuticals Inc insiders were filed in the last 90 days; 122 institutions reported holding it in 13F filings for Q2 2026, worth $397.2M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Enanta Pharmaceuticals Inc changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 108 | 122 | +14 |
| Shares | 18.4M | 19.0M | +549.7K (+3.0%) |
| Value | $139.4M | $227.1M | +$87.7M (+62.9%) |
New holders (25)
Institutions that held Enanta Pharmaceuticals Inc at the end of Q3 2025 but not at the end of Q2 2025.
Sold out (11)
Institutions that held Enanta Pharmaceuticals Inc at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Sio Capital Management, LLC | 178,774 | $1.35M |
| UBS Asset Management Americas Inc | 149,178 | $1.13M |
| Citadel Advisors LLC | 59,144 | $447.1K |
| Virtu Financial LLC | 31,533 | $238.0K |
| Sanctuary Advisors, LLC | 25,427 | $192.2K |
| Sherbrooke Park Advisers LLC | 12,538 | $94.8K |
| Intech Investment Management LLC | 11,101 | $83.9K |
| US Bancorp | 5,916 | $44.7K |
| Caitong International Asset Management Co., Ltd | 195 | $1.47K |
| Fifth Third Bancorp | 111 | $839 |
| Raymond James Financial Inc | 50 | $378 |